Introduction

Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3, is a rare inherited neurological disorder that progressively affects muscle control and coordination. If you or a loved one is living with MJD, you know that day-to-day symptoms like balance problems, muscle stiffness, and speech difficulties can significantly impact quality of life. While there is currently no cure for MJD, there are many ways to manage its symptoms and help you maintain independence and comfort. In fact, treating the symptoms—from movement issues to pain and sleep problems—is the cornerstone of care for MJD. This approachable guide will walk you through the current treatments used to ease MJD symptoms, including medications, therapies, assistive devices, and some emerging approaches. By understanding these options, you can work with your healthcare team to create a plan that best supports you.

Overview of machado-joseph disease

Figure (optional): Common symptoms of Machado-Joseph disease include cerebellar ataxia (loss of balance and coordination), muscle stiffness or spasticity, eye movement problems (ophthalmoplegia and nystagmus), slurred speech (dysarthria), and dystonia (involuntary muscle contractions). Cognitive function is typically preserved, indicating that MJD primarily affects physical abilities.

MJD is the most common form of hereditary spinocerebellar ataxia worldwide. It is caused by a gene mutation that leads to abnormal proteins accumulating in certain brain cells, especially those in the cerebellum (the balance and coordination centre). As a result, ataxia develops—a condition characterised by a lack of coordination that makes walking and maintaining balance difficult. People with MJD often notice unsteady gait and clumsiness as early symptoms. Over time, MJD can also cause muscle stiffness or spasticity (resulting from pyramidal tract involvement), eye movement difficulties (ophthalmoplegia, leading to double vision), and speech/swallowing difficulties (dysarthria and dysphagia) due to muscle incoordination.
In some individuals, MJD produces Parkinson-like symptoms (slowness, tremor) or dystonia (involuntary muscle contractions). Other common issues include peripheral neuropathy (characterised by numbness/tingling), muscle cramps, fatigue, and chronic pain. Cognitive abilities are usually preserved. MJD typically begins in mid-adulthood and progresses over the years. Because no treatment yet halts disease progression, symptom management is crucial to improve day-to-day function, safety, and overall quality of life.

Pharmacological approaches to symptom management

Medications cannot cure MJD, but they can significantly relieve many of its symptoms. Most symptoms—muscle spasticity, pain, fatigue, depression, sleep disturbances, and bladder/bowel issues—have one or more evidence-based options that clinicians tailor to the individual. 

Muscle stiffness and spasticity. If MJD causes stiffness, cramps, or spasms (e.g., in the legs or neck), doctors often prescribe muscle relaxants. Baclofen is commonly used to reduce muscle tone and spasms; tizanidine or diazepam may also be considered. For severe focal spasticity or painful dystonia, botulinum toxin injections into overactive muscles (e.g., the neck, periocular area) can provide targeted relief.

Tremors and movement problems. Although no anti-tremor drug is approved specifically for MJD, clinicians often borrow from other movement disorders. Low-dose clonazepam or propranolol may help with tremor. If Parkinson-like symptoms occur (slowness, rigidity, tremor), standard levodopa (with carbidopa) can sometimes improve rigidity/slowness; dopamine agonists or anticholinergics may be considered case-by-case basis. Responses vary, but short trials are reasonable because a subset obtains meaningful relief.

Pain management. Chronic pain is increasingly recognised in MJD and may be musculoskeletal, neuropathic, or secondary to dystonia/spasticity. Management starts with identifying the mechanism. Simple analgesics (paracetamol/NSAIDs) are suitable for nociceptive pain; gabapentin or amitriptyline can target neuropathic pain; and treating dystonia/spasticity (e.g., botulinum toxin, muscle relaxants) often eases secondary pain. Opioids are reserved for refractory, severe cases. 

Muscle cramps. Frequent painful cramps (calves/feet) may respond to mexiletine or carbamazepine (off-label, with appropriate monitoring). Reducing cramps can improve sleep and daytime comfort.

Sleep problems and restless legs. Sleep disturbance can relate to immobility, pain, mood, or specific disorders. If restless legs syndrome (RLS) is present, evening dopamine agonists (such as pramipexole/ropinirole) or low-dose levodopa can be helpful. Evaluate for sleep apnoea and iron deficiency where relevant, and reinforce sleep hygiene.

Fatigue. Optimise sleep, treat mood symptoms, address pain/cramps, and use pacing. Some clinicians trial modafinil or methylphenidate for excessive daytime sleepiness/fatigue when these limit participation in therapy and daily activities.

Depression and mood. Depression and anxiety are common and strongly affect quality of life and engagement with rehabilitation. Treat per standard practice with SSRIs/SNRIs and psychological therapies (e.g., CBT).

Other symptom-specific treatments. Manage bladder urgency/incontinence (e.g., antimuscarinics), constipation (diet, fluids, laxatives), and double vision (prism lenses). Rare cases of orthostatic hypotension can be managed with conservative measures and midodrine, if needed.
Key point: No medicine reliably restores cerebellar coordination; medications work best alongside rehabilitation and safety strategies.

Non-pharmacological approaches to symptom management

Non-drug strategies are foundational: they help you adapt to changes and maintain independence, without medication side effects.

Physical therapy (physiotherapy). Regular physiotherapy is one of the most beneficial interventions in MJD. Intensive balance/coordination training and task-specific gait work can reduce ataxia severity and improve stability in degenerative cerebellar ataxias (including SCA3). Typical programmes include gait training (with/without assistive devices), static/dynamic balance tasks, limb coordination drills, strengthening, and fall-recovery practice. Aerobic activity (e.g., stationary cycling, aquatic exercise) helps endurance and may support motor learning. Consistency and progression are key.

Occupational therapy. OTs help tailor daily activities to your abilities with energy-conservation strategies and assistive tools (grab bars, shower chairs, raised toilet seats, jar openers, thick-handled utensils, button hooks, elastic laces). Environmental changes (decluttering, lighting, and non-slip mats) and workstation adaptations support function and safety at home and in the workplace.

Speech and language therapy. For individuals with dysarthria, therapists employ breath support, articulation drills, rate control, and communication strategies. Early use of augmentative and alternative communication (AAC)—from alphabet boards to text-to-speech apps—helps maintain participation and engagement. For dysphagia, therapists assess swallow function (and, if indicated, videofluoroscopy) and recommend diet texture changes, compensatory postures, and safe-swallow techniques to reduce aspiration.

Assistive devices for mobility. Introduce aids proactively to reduce falls and extend independence: a cane for early imbalance; a walker/rollator as unsteadiness progresses (rollators provide a rest seat); and a wheelchair/scooter for long distances or severe fatigue. Embracing the right aid at the right time can prevent injuries and often increase activity. Combine with home modifications (ramps, rails, lighting, non-slip flooring) and a review of footwear.

Lifestyle and wellness strategies. Stay as active as safely possible; choose low-impact options that fit your abilities. Avoid alcohol and sedatives that worsen ataxia. Optimise nutrition (dietitian input if weight loss occurs with dysphagia). Use pacing and planned rest to manage fatigue. Maintain social connections and consider ataxia support groups. Include genetic counselling for family planning (autosomal dominant inheritance; ~50% risk to children). 

Emerging therapies and clinical trials

Current treatments are symptomatic, but research is pushing toward disease-modifying strategies.

Gene-silencing therapies (antisense oligonucleotides, ASOs). Because the expanded ATXN3 gene drives pathology, reducing mutant ataxin-3 is a direct approach to addressing the condition. In SCA3 mouse models, anti-ATXN3 ASOs reduced pathology and improved motor outcomes, supporting early human trials assessing safety and biomarker effects.

Repurposed/neuroprotective agents:

• Varenicline (a partial nicotinic agonist) improved gait/balance subscores and depressive symptoms over 8 weeks in a small randomised SCA3 trial
• Valproic acid (HDAC-inhibiting anticonvulsant/mood stabiliser) produced modest SARA improvements over 12 weeks in a placebo-controlled SCA3 study, though side-effects and variable responses limit routine use

Other exploratory avenues. Trials/small studies have examined riluzole/troriluzole, buspirone, antioxidants (e.g., coenzyme Q10, idebenone), non-invasive brain stimulation (cerebellar TMS/tDCS), and cell-based therapies; however, evidence remains preliminary, and none are currently standard of care. Bottom line: while these approaches are not routine today, participation in clinical trials (search terms: “Machado-Joseph” or “SCA3”) may provide access to cutting-edge therapies and help advance the field.

Summary

Symptom management in MJD pairs targeted medications with rehabilitation, assistive technology, and lifestyle measures to reduce symptoms, prevent complications, and preserve independence. Medications address spasticity/dystonia, tremor/parkinsonism, pain, cramps, sleep/RLS, fatigue, and mood; rehab (physiotherapy, OT, speech therapy) is central for balance/coordination, daily activities, and communication/swallowing; mobility aids and home modifications reduce falls and often increase participation rather than limit it; and supportive strategies (exercise, nutrition, pacing, social connection) plus genetic counselling round out care.

Emerging gene-targeted therapies and selectively repurposed medications are paving the way for innovative approaches to disease modification. These advancements offer realistic hope for effectively changing the course of certain diseases. However, despite their promising potential, these treatments have not yet become routine in clinical practice. As research continues and these therapies undergo further testing and development, we are optimistic about their eventual integration into standard healthcare options for patients.